Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer

Breast Cancer Research and Treatment

Volumn 125, Issue 3, 2011, Pages 775-784

  Amadori, Dino ^a   Silvestrini, Rosella ^a   De Lena, Mario ^b   Boccardo, Francesco ^c   Rocca, Andrea ^a   Scarpi, Emanuela ^a   Schittulli, Francesco ^b   Brandi, Mario ^b   Maltoni, Roberta ^a   Serra, Patrizia ^a   Ponzone, Riccardo ^d   Biglia, Nicoletta ^d   Gianni, Lorenzo ^e   Tienghi, Amelia ^f   Valerio, Maria Rosaria ^g   Bonginelli, Paola ^h   Amaducci, Laura ⁱ   Faedi, Marina ^j   Baldini, Editta ^k   Paradiso, Angelo ^b  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e Ospedale Per Gli Infermi   (Italy)

^f SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

^h SAN FILIPPO NERI HOSPITAL   (Italy)

ⁱ Degli Infermi Hospital   (Italy)

^j BUFALINI HOSPITAL   (Italy)

^k UNIVERSITY OF PISA   (Italy)

more..

Author keywords

CMF; Epirubicin; Randomized phase III study; Rapidly proliferating breast cancer; Sequential adjuvant chemotherapy strategy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN; FLUOROURACIL; GONADORELIN AGONIST; METHOTREXATE; TAMOXIFEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; AMENORRHEA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONSERVATIVE TREATMENT; DERMATITIS; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HEART DISEASE; HEPATITIS C; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LIVER TOXICITY; MASTECTOMY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OSTEOARTHROPATHY; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; MODELS, BIOLOGICAL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 79151474153     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1257-5     Document Type: Article

References (35)

1. A Goldhirsch JN Ingle RD Gelber AS Coates B Thürlimann HJ Senn 2009 Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 1319 1329 1:STN:280:DC%2BD1Mrjtlyhug%3D%3D 10.1093/annonc/mdp322 19535820
2. D Amadori A Volpi R Maltoni O Nanni L Amaducci A Amadori DC Giunchi A Vio A Saragoni R Silvestrini 1997 Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study Breast Cancer Res Treat 43 7 14 1:STN:280:DyaK2s3hsl2gsQ%3D%3D 10.1023/A:1005780107879 9065594 (Pubitemid 27090862)
3. D Amadori O Nanni M Marangolo P Pacini A Ravaioli A Rossi A Gambi G Catalano D Perroni E Scarpi DC Giunchi A Tienghi A Becciolini A Volpi 2000 Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study J Clin Oncol 18 3125 3134 1:CAS:528:DC%2BD3cXntVCgsb0%3D 10963641
4. D Amadori O Nanni A Volpi P Pacini A Ravaioli AP Rossi A Gambi S Luzi Fedeli D Perroni E Scarpi A Becciolini R Silvestrini 2008 Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis Breast Cancer Res Treat 108 259 264 1:CAS:528: DC%2BD1cXitleqsbo%3D 10.1007/s10549-007-9593-9 17530429 (Pubitemid 351311359)
5. G Minotti P Menna E Salvatorelli G Cairo L Gianni 2009 Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 185 229 10.1124/pr.56.2.6
6. Gilewski T, Norton L (1996) Cytokinetics and breast cancer chemotherapy. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the breast. Lippincott-Raven, Philadelphia
7. G Bonadonna M Zambetti P Valagussa 1995 Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results JAMA 273 542 547 1:STN:280:DyaK2M7jvFWqtw%3D%3D 10.1001/jama.273.7.542 7837388
8. R Silvestrini A Luisi M Zambetti S Cipriani P Valagussa G Bonadonna MG Daidone 2000 Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer Int J Cancer 87 405 411 1:CAS:528:DC%2BD3cXltFOnsbo%3D 10.1002/1097-0215(20000801)87:3<405::AID- IJC15>3.0.CO;2-# 10897047 (Pubitemid 30451653)
9. R Silvestrini MG Daidone A Luisi P Boracchi M Mezzetti G Di Fronzo S Andreola U Veronesi 1995 Biologic and clinico-pathologic factors as indicators of specific relapse types in node-negative breast cancer J Clin Oncol 13 697 704 1:STN:280:DyaK2M7ptVGhsg%3D%3D 7884430
10. R Silvestrini MG Daidone A Luisi M Mastore M Leutner B Salvadori 1997 Cell proliferation in 3, 800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index Int J Cancer 74 122 127 1:STN:280:DyaK2s7ovVaqtw%3D%3D 10.1002/(SICI)1097- 0215(19970220)74:1<122::AID-IJC20>3.0.CO;2-G 9036880 (Pubitemid 27157866)
11. F Barzanti M Dal Susino A Volpi D Amadori A Riccobon E Scarpi L Medri L Bernardi S Naldi M Aldi M Gaudio W Zoli 2000 Comparison between different cell kinetic variables in human breast cancer Cell Prolif 33 75 89 1:STN:280:DC%2BD3czgtFylsA%3D%3D 10.1046/j.1365-2184.2000.00165.x 10845252 (Pubitemid 30307236)
12. Early Breast Cancer Trialists' Collaborative Group 1998 Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930 942 10.1016/S0140-6736(98)03301-7 (Pubitemid 28427277)
13. A Piffanelli D Pellizzola G Giovannini L Catozzi L Faggioli M Giganti 1989 Characterization of laboratory working standard for quality control of immunometric and radiometric estrogen receptor assays. Clinical evaluation on breast cancer biopsies. Italian Committee for Hormone Receptor Assays Standardization Tumori 75 550 556 1:STN:280:DyaK3c7kt1Whtw%3D%3D 2482565
14. A Volpi F Bacci A Paradiso L Saragoni E Scarpi M Ricci M Aldi S Bianchi P Muretto F Nuzzo G Simone A Mangia F Schittulli D Amadori 2004 Prognostic relevance of histological grade and its components in node-negative breast cancer patients Mod Pathol 17 1038 1044 10.1038/modpathol.3800161 15154006 (Pubitemid 39128229)
15. World Health Organization: World Health Organization handbook for reporting results of cancer treatment (1979). World Health Organization, Geneva
16. International Conference on Harmonisation of Technical Requirement for Requirements for Registration of Pharmaceuticals for Human Use (ICH Harmonised Tripartite Guidelines): Guideline for good clinical practice (GCP) E6 (1996). http://www.ich.org/LOB/media/MEDIA482.pdf. Accessed 1 February 2009
17. World Medical Association Declaration of Helsinki (1996) Recommendations guiding physician in biomedical research involving human subjects, adopted by the 18th World Medical Assembly Helsinki, Finland, June amended by 48th General Assembly, Somerset West, South Africa. http://www.wma.net/e/polity/pdf/17cpdf. Accessed 1 February 2009
18. El Kaplan P Meier 1958 Nonparametric estimation for incomplete observation J Am Stat Assoc 53 457 481 10.2307/2281868
19. Armitage P, Berry G, Matthews JNS (2000) Statistical methods in medical research, 4th edn. Blackwell Publishing, Oxford
20. DR Cox 1972 Regression models and life tables J R Stat Soc 34 187 220
21. R Buzzoni G Bonadonna P Valagussa M Zambetti 1991 Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes J Clin Oncol 9 2134 2140 1:STN:280:DyaK38%2FntFOnug%3D%3D 1960555
22. M Martin 2009 Unravelling the mystery of the TACT trial Lancet 373 1662 1663 10.1016/S0140-6736(09)60925-9 19447241
23. RS Day 1986 Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy Cancer Res 46 3876 3885 1:CAS:528:DyaL28XkslahtLk%3D 3731062
24. F Valeriote L van Putten 1975 Proliferation-dependent cytotoxicity of anticancer agents: a review Cancer Res 35 2619 2630 1:CAS:528:DyaE2MXmtVWltbw%3D 1098765
25. YH Ling AK el-Naggar W Priebe R Perez-Soler 1996 Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells Mol Pharmacol 49 832 841 1:CAS:528:DyaK28XjtVKhsL0%3D 8622633
26. R Silvestrini MG Daidone P Valagussa B Salvadori D Rovini G Bonadonna 1987 Cell kinetics as a prognostic marker in locally advanced breast cancer Cancer Treat Rep 71 375 379 1:STN:280:DyaL2s7lvFeitg%3D%3D 3829014
27. A Paradiso F Schittulli G Cellamare A Mangia F Marzullo V Lorusso M De Lena 2001 Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer J Clin Oncol 19 3929 3937 1:CAS:528: DC%2BD3MXnslKlu7k%3D 11579113
28. MG Daidone R Silvestrini A Luisi M Mastore E Benini S Veneroni C Brambilla L Ferrari M Greco S Andreola 1995 Changes in biological markers after primary chemotherapy for breast cancers Int J Cancer 61 301 305 1:STN:280:DyaK2M3kslehsg%3D%3D 10.1002/ijc.2910610304 7729938
29. Y Remvikos M Jouve P Beuzeboc P Viehl H Magdelenat P Pouillart 1993 Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates Eur J Cancer 29A 1843 1848 1:STN:280:DyaK2c%2FotlWhtA%3D%3D 10.1016/0959-8049(93)90534-M 8260238 (Pubitemid 23288025)
30. A Moliterni G Bonadonna P Valagussa L Ferrari M Zambetti 1991 Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes J Clin Oncol 9 1124 1130 1:STN:280:DyaK3M3lvFWlsw%3D%3D 2045854
31. RD Woessner MR Mattern CK Mirabelli RK Johnson FH Drake 1991 Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells Cell Growth Differ 2 209 214 1:CAS:528:DyaK38Xls1arsg%3D%3D 1651102
32. C Negri R Chiesa A Cerino M Bestagno C Sala N Zini NM Maraldi GC Astaldi Ricotti 1992 Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes Exp Cell Res 200 452 459 1:CAS:528:DyaK38XisFeksbw%3D 10.1016/0014-4827(92)90195-E 1315288
33. M Colozza E Azambuja F Cardoso C Sotiriou D Larsimont MJ Piccart 2005 Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 6 1723 1739 10.1093/annonc/mdi352 (Pubitemid 41631235)
34. R Silvestrini 1991 Feasibility and reproducibility of the 3H-thymidine labeling index in breast cancer. The SICCAB Group for Quality Control of Cell Kinetic determination Cell Prolif 24 437 445 1:STN:280:DyaK38%2Fjt1SrtQ%3D%3D 10.1111/j.1365-2184.1991.tb01172.x 1932355
35. E de Azambuja F Cardoso G de Castro Jr M Colozza MS Mano V Durbecq C Sotiriou D Larsimont MJ Piccart-Gebhart M Paesmans 2007 Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients Br J Cancer 96 1504 1513 10.1038/sj.bjc.6603756 17453008 (Pubitemid 46762956)